open access

Vol 10, No 3 (2014)
Review paper
Published online: 2014-07-30
Get Citation

Enzalutamide in treatment of castrate-resistant prostate cancer

Jakub Żołnierek
Onkol. Prak. Klin 2014;10(3):148-151.

open access

Vol 10, No 3 (2014)
REVIEW ARTICLES
Published online: 2014-07-30

Abstract

Prostate cancer is one of the most common tumours in men. Castrate resistance of prostate cancer (CRPC) is a serious clinical problem.

Progress in the field of molecular biology enabled identification of the crucial role of signal transduction pathway dependent on the androgen receptor (AR) in CRPC. Enzalutamide is the first anti-androgen that interferes with mechanism of progression related to AR gene amplification and/or AR over-expression. The results of PREVAIL — phase 3 trial in population of men with metastatic CRPC not previously exposed to docetaxel were presented on ASCO GU 2014. These data prove significant advantage of enzalutamide use over placebo in regards to all study end-points.

Enzalutamide is the only drug that prolongs survival in men with CRPC not previously treated with docetaxel.

Abstract

Prostate cancer is one of the most common tumours in men. Castrate resistance of prostate cancer (CRPC) is a serious clinical problem.

Progress in the field of molecular biology enabled identification of the crucial role of signal transduction pathway dependent on the androgen receptor (AR) in CRPC. Enzalutamide is the first anti-androgen that interferes with mechanism of progression related to AR gene amplification and/or AR over-expression. The results of PREVAIL — phase 3 trial in population of men with metastatic CRPC not previously exposed to docetaxel were presented on ASCO GU 2014. These data prove significant advantage of enzalutamide use over placebo in regards to all study end-points.

Enzalutamide is the only drug that prolongs survival in men with CRPC not previously treated with docetaxel.

Get Citation

Keywords

castrate-resistant prostate cancer, androgen receptor, enzalutamide

About this article
Title

Enzalutamide in treatment of castrate-resistant prostate cancer

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 3 (2014)

Article type

Review paper

Pages

148-151

Published online

2014-07-30

Bibliographic record

Onkol. Prak. Klin 2014;10(3):148-151.

Keywords

castrate-resistant prostate cancer
androgen receptor
enzalutamide

Authors

Jakub Żołnierek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl